All treatments
Treatment
Nivo 240 mg and Rela 80 mg per vial clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
This study looks at a new combination treatment for advanced melanoma that has been removed by surgery. It compares two drugs given together (nivolumab and relatlimab) against nivolumab alone, to see if the combination can help prevent the cancer from coming back.
For: Participants with completely resected Stage III or Stage IV melanomaCzechia · Denmark · Belgium - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
This study is looking at a new treatment for advanced cancers. We're testing a new drug, BMS-986016, alone and with an existing cancer drug, Nivolumab, to see how safe and effective they are. It's a key first step in understanding these potential new treatments.
For: Neoplasms by siteFinland · Norway · Denmark